Copyright Reports & Markets. All rights reserved.

Global Polymyositis Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Polymyositis Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Immunosuppressant
      • 1.4.3 Alkylating Agent
      • 1.4.4 Immunoglobulin
      • 1.4.5 Monoclonal Antibodies
      • 1.4.6 Corticosteroids
    • 1.5 Market by Application
      • 1.5.1 Global Polymyositis Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Polymyositis Treatment Market Size
    • 2.2 Polymyositis Treatment Growth Trends by Regions
      • 2.2.1 Polymyositis Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Polymyositis Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Polymyositis Treatment Market Size by by Players
      • 3.1.1 Global Polymyositis Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Polymyositis Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Polymyositis Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Polymyositis Treatment Key Players Head office and Area Served
    • 3.3 Key Players Polymyositis Treatment Product/Solution/Service
    • 3.4 Date of Enter into Polymyositis Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Polymyositis Treatment Market Size by Type (2014-2019)
    • 4.2 Global Polymyositis Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Polymyositis Treatment Market Size (2014-2019)
    • 5.2 Polymyositis Treatment Key Players in North America
    • 5.3 North America Polymyositis Treatment Market Size by Type
    • 5.4 North America Polymyositis Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Polymyositis Treatment Market Size (2014-2019)
    • 6.2 Polymyositis Treatment Key Players in Europe
    • 6.3 Europe Polymyositis Treatment Market Size by Type
    • 6.4 Europe Polymyositis Treatment Market Size by Application

    7 China

    • 7.1 China Polymyositis Treatment Market Size (2014-2019)
    • 7.2 Polymyositis Treatment Key Players in China
    • 7.3 China Polymyositis Treatment Market Size by Type
    • 7.4 China Polymyositis Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Polymyositis Treatment Market Size (2014-2019)
    • 8.2 Polymyositis Treatment Key Players in Japan
    • 8.3 Japan Polymyositis Treatment Market Size by Type
    • 8.4 Japan Polymyositis Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Polymyositis Treatment Market Size (2014-2019)
    • 9.2 Polymyositis Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Polymyositis Treatment Market Size by Type
    • 9.4 Southeast Asia Polymyositis Treatment Market Size by Application

    10 India

    • 10.1 India Polymyositis Treatment Market Size (2014-2019)
    • 10.2 Polymyositis Treatment Key Players in India
    • 10.3 India Polymyositis Treatment Market Size by Type
    • 10.4 India Polymyositis Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Polymyositis Treatment Market Size (2014-2019)
    • 11.2 Polymyositis Treatment Key Players in Central & South America
    • 11.3 Central & South America Polymyositis Treatment Market Size by Type
    • 11.4 Central & South America Polymyositis Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Hospira, Inc.
      • 12.1.1 Hospira, Inc. Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Polymyositis Treatment Introduction
      • 12.1.4 Hospira, Inc. Revenue in Polymyositis Treatment Business (2014-2019))
      • 12.1.5 Hospira, Inc. Recent Development
    • 12.2 Antares Pharma, Inc.
      • 12.2.1 Antares Pharma, Inc. Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Polymyositis Treatment Introduction
      • 12.2.4 Antares Pharma, Inc. Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.2.5 Antares Pharma, Inc. Recent Development
    • 12.3 Medexus Pharma, Inc.
      • 12.3.1 Medexus Pharma, Inc. Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Polymyositis Treatment Introduction
      • 12.3.4 Medexus Pharma, Inc. Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.3.5 Medexus Pharma, Inc. Recent Development
    • 12.4 Fresenius SE & Co. KGaA
      • 12.4.1 Fresenius SE & Co. KGaA Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Polymyositis Treatment Introduction
      • 12.4.4 Fresenius SE & Co. KGaA Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.4.5 Fresenius SE & Co. KGaA Recent Development
    • 12.5 Mylan N.V.
      • 12.5.1 Mylan N.V. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Polymyositis Treatment Introduction
      • 12.5.4 Mylan N.V. Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.5.5 Mylan N.V. Recent Development
    • 12.6 Alcami Corporation
      • 12.6.1 Alcami Corporation Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Polymyositis Treatment Introduction
      • 12.6.4 Alcami Corporation Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.6.5 Alcami Corporation Recent Development
    • 12.7 Teva Pharmaceuticals
      • 12.7.1 Teva Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Polymyositis Treatment Introduction
      • 12.7.4 Teva Pharmaceuticals Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.7.5 Teva Pharmaceuticals Recent Development
    • 12.8 Novartis AG
      • 12.8.1 Novartis AG Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Polymyositis Treatment Introduction
      • 12.8.4 Novartis AG Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.8.5 Novartis AG Recent Development
    • 12.9 Genentech, Inc.
      • 12.9.1 Genentech, Inc. Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Polymyositis Treatment Introduction
      • 12.9.4 Genentech, Inc. Revenue in Polymyositis Treatment Business (2014-2019)
      • 12.9.5 Genentech, Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Polymyositis (PM) is a type of chronic inflammation of the muscles (inflammatory myopathy) related to dermatomyositis and inclusion body myositis. Its name means "inflammation of many muscles" (poly- + myos- + -itis).
      In 2018, the global Polymyositis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Polymyositis Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Polymyositis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Hospira, Inc.
      Antares Pharma, Inc.
      Medexus Pharma, Inc.
      Fresenius SE & Co. KGaA
      Mylan N.V.
      Alcami Corporation
      Teva Pharmaceuticals
      Novartis AG
      Genentech, Inc.

      Market segment by Type, the product can be split into
      Immunosuppressant
      Alkylating Agent
      Immunoglobulin
      Monoclonal Antibodies
      Corticosteroids

      Market segment by Application, split into
      Hospitals
      Clinic
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Polymyositis Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Polymyositis Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Polymyositis Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now